免疫检查点B7-H3是携带PTEN和TP53缺陷的前列腺癌的治疗脆弱点
多组学分析发现B7-H3是PTEN和TP53基因失活前列腺肿瘤中丰度最高的免疫检查点之一;PTEN和TP53缺失通过激活转录因子Sp1诱导B7-H3表达。在前列腺特异性敲除Cd276的Pten/Trp53基因工程小鼠模型中,肿瘤进展延迟,肿瘤浸润T细胞和NK细胞受抑状态被逆转。在去势抵抗性前列腺癌临床前模型中,调节性T细胞富集和髓系细胞PD-L1升高削弱B7-H3抑制疗效;B7-H3抑制联合PD-L1或CTLA-4阻断在PTEN/TP53缺陷CRPC模型中取得持久抗肿瘤效果并具治愈潜力。
要点
- PTEN和TP53失活通过Sp1诱导前列腺癌B7-H3高表达。
- 前列腺特异性敲除Cd276可延迟Pten/Trp53小鼠肿瘤进展并逆转T细胞和NK细胞抑制。
- 调节性T细胞富集和髓系PD-L1升高削弱B7-H3抑制疗效。
核心结论
- B7-H3是PTEN和TP53缺陷前列腺癌的治疗脆弱点,B7-H3靶向联合PD-L1或CTLA-4阻断在临床前模型中显示持久抗肿瘤效果和治愈潜力。
研究设计与样本
- 研究采用多组学分析、基因工程小鼠模型和去势抵抗性前列腺癌临床前模型,探讨B7-H3在PTEN/TP53缺陷前列腺癌中的作用及联合治疗策略。
主要发现
- 多组学分析鉴定B7-H3为含PTEN和TP53基因失活的前列腺肿瘤中丰度最高的免疫检查点之一。
- PTEN和TP53缺失通过激活转录因子Sp1诱导B7-H3表达。
- 前列腺特异性敲除Cd276导致Pten/Trp53基因工程小鼠模型肿瘤进展延迟,并逆转肿瘤浸润T细胞和NK细胞的抑制。
- 在去势抵抗性前列腺癌临床前模型中,调节性T细胞富集和髓系细胞PD-L1升高削弱B7-H3抑制的疗效。
- B7-H3抑制联合PD-L1或CTLA-4阻断在PTEN/TP53缺陷CRPC模型中实现持久抗肿瘤效果并具治愈潜力。
临床怎么用
- B7-H3靶向治疗已在早期临床试验中评估,本研究为前列腺癌及其他恶性肿瘤中靶向B7-H3的生物标志物驱动联合免疫治疗提供见解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Checkpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and has emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3's role in cancer progression, predictive biomarkers for B7-H3-targeted therapy, and combinatorial strategies. Our multi-omics analyses identified B7-H3 as one of the most abundant immune checkpoints in prostate tumors containing PTEN and TP53 genetic inactivation. Here, we sought in vivo genetic evidence for, and mechanistic understanding of, the role of B7-H3 in PTEN/TP53-deficient prostate cancer. We found that loss of PTEN and TP53 induced B7-H3 expression by activating transcriptional factor Sp1. Prostate-specific deletion of Cd276 resulted in delayed tumor progression and reversed the suppression of tumor-infiltrating T cells and NK cells in Pten/Trp53 genetically engineered mouse models. Furthermore, we tested the efficacy of the B7-H3 inhibitor in preclinical models of castration-resistant prostate cancer (CRPC). We demonstrated that enriched regulatory T cells and elevated programmed cell death ligand 1 (PD-L1) in myeloid cells hinder the therapeutic efficacy of B7-H3 inhibition in prostate tumors. Last, we showed that B7-H3 inhibition combined with blockade of PD-L1 or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) achieved durable antitumor effects and had curative potential in a PTEN/TP53-deficient CRPC model. Given that B7-H3-targeted therapies have been evaluated in early clinical trials, our studies provide insights into the potential of biomarker-driven combinatorial immunotherapy targeting B7-H3 in prostate cancer, among other malignancies.
引用
- Shi W, Wang Y, Zhao Y, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023. PMID: 37163614. doi:10.1126/scitranslmed.adf6724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。